Key Points {#FPar1}
==========

Remarkable progress has been made in understanding the molecular genetics and underlying pathomechanisms of epidermolysis bullosa (EB) forming the platform for development of treatments.Gene-replacement approaches, particularly delivery of *COL7A1* to the skin of patients with severe dystrophic EB, type VII collagen replacement, skipping of exons and read-through of premature termination codons are currently in clinical trials.Preclinical research explores the applicability of new strategies in regenerative medicine (e.g., induced pluripotent stem cells) and genome editing (e.g., CRISPR/Cas9).Particular effort is focused on severe dystrophic EB, characterized by extensive scarring and aggressive squamous cell carcinomas. Small molecules repurposed to reduce fibrosis, and the multikinase inhibitor rigosertib---for the treatment of recessive dystrophic EB squamous cell carcinomas---are being tested in clinical trials.

Introduction {#Sec1}
============

Epidermolysis bullosa (EB) comprises a group of genetic disorders characterized by fragility of the skin and mucosal membranes. The molecular basis involves pathogenic variants in genes encoding structural proteins of the dermal--epidermal junction zone (DEJZ) \[[@CR1]\]. As a consequence of missing or dysfunctional molecules (e.g., keratins 5/14, integrin α6β4, type XVII and VII collagens), reduced epidermal--dermal cohesion results in blisters after minimal mechanical trauma. The clinical severity of EB covers a broad spectrum, ranging from minor skin or nail involvement and minimal disease burden in localized subtypes to early lethality or life-long progressive systemic disease in severe subtypes \[[@CR2]\].

EB is a prototypic disorder for which molecular therapies have been under development in the last few decades. Significant progress has been achieved in understanding the molecular pathogenesis of EB and the potential benefits and limitations of different therapeutic approaches \[[@CR3]\]. Considering that EB is a rare disease, a relatively large number of clinical trials are ongoing and ascertaining the clinical efficacy of gene, protein or cell therapies or of repurposed drugs (Table [1](#Tab1){ref-type="table"}). In parallel, preclinical research explores the applicability of new strategies in regenerative medicine (e.g., induced pluripotent stem cells \[iPSCs\]) and genome editing (e.g., CRISPR/Cas9) (Table [2](#Tab2){ref-type="table"}). However, the initial hope of rapid translation from bench to bedside has been tempered by multiple hurdles and challenges, including the complexity of EB itself. Thus, instead of attempting to cure EB, researchers are increasingly aiming at "symptom-relieving" or "disease-modifying" therapies.Table 1Gene-replacement therapies for epidermolysis bullosa in clinical trialsGene therapy trialEB type/proteinApproachParticipants (N)ResultsReferencesPhase IJEB/laminin β3 chain*Ex vivo* genetically corrected (retroviral) autologous epidermal grafts2One 7-year-old child treated in wounds covering 80% of the total body surface resulted in regeneration of entire epidermis by transgenic stem cells stable over several years. One 49-year-old woman was successfully treated on an 80 cm^2^ chronic wound\[[@CR35], [@CR36]\]Phase I/II; NCT03490331(HOLOGENE17)JEB/C17*Ex vivo* grafting of gene‐corrected epidermal sheets with a gamma‐retroviral vector carrying *COL17A1* cDNA12Ongoing\[[@CR91]\]<https://clinicaltrials.gov/ct2/show/NCT03490331>Phase I/II; NCT02984085(HOLOGENE7)RDEB/C7*Ex vivo* grafting of gene‐corrected epidermal sheets with a gamma‐retroviral vector carrying *COL7A1* cDNA12Ongoing\[[@CR91]\]<https://clinicaltrials.gov/ct2/show/NCT02984085>Phase I; safety and wound outcomes; single centerRDEB/C7*Ex vivo* genetically corrected (retroviral) autologous epidermal grafts of 35 cm^2^4Variable response of wound healing and C7; generally declined over 1 year\[[@CR30]\]Phase I/IIa; single centerRDEB/C7*Ex vivo* genetically corrected (retroviral) autologous epidermal grafts of 35 cm^2^7C7 expression persisted up to 2 years after treatment in two participants. Treated wounds with ≥ 50% healing demonstrated improvement in patient-reported pain, itch, and wound durability\[[@CR29]\]Phase I; single centerRDEB/C7Three intradermal injections (\~ 1 × 10^6^ cells/cm^2^ of intact skin) of *COL7A1*-modified (lentiviral) autologous fibroblasts4C7 restoration in vivo in treated skin at 1 year after gene therapy\[[@CR92]\]Phase I/II, phase III; NCT04213261 (Castle Creek Biosciences, Inc.)RDEB/C7*COL7A1*-corrected autologous fibroblasts injected in the wounds20Ongoing<https://clinicaltrials.gov/ct2/show/NCT04213261>Phase III; NCT04227106 (Abeona Therapeutics Inc.)RDEB/C7Transplantation of ex vivo *COL7A1*-corrected autologous keratinocyte sheets15Ongoing<https://clinicaltrials.gov/ct2/show/NCT04227106>Phase I/II; European (GENEGRAFT)RDEB/C7Skin-equivalent grafts ex vivo genetically corrected with a *COL7A1*-encoding SIN retroviral vector4Ongoing\[[@CR33]\]Phase I/II; NCT03536143 (Krystall Biotech, Inc.)RDEB/C7Topically administered, replication-deficient HSV-1 vector containing two functional *COL7A1* genes applied directly to wounds6Ongoing[www.krystalbio.com/focus/about-dystrophic-eb/](http://www.krystalbio.com/focus/about-dystrophic-eb/)Phase I (Amryt Pharma, PLC)RDEB/C7Topically administered synthetic polymer polyplexes containing *COL7A1*, applied directly to woundsNANA<https://www.amrytpharma.com/patients-and-carers/gene-therapy/>*cDNA* complementary DNA, *C7* type VII collagen, *C17* type XVII collagen, *EB* epidermolysis bullosa, *HSV*-*1* herpes simplex virus type 1, *JEB* junctional EB, *NA* not available, *RDEB* recessive dystrophic EB, *SIN* self-inactivatingTable 2Overview of recently published CRISPR/Cas9- and RNA-based molecular therapies in preclinical developmentMolecular therapy approachEB type/geneCorrection type, targeted mutation and cellsReferencesGenomic editing using the CRISPR/Cas9 nuclease systemRDEB/*COL7A1COL7A1* overexpression\[[@CR93]\]Correction of a mutation in exon 2\[[@CR41]\]Correction of the mutation c.4317delC and generation of iPSC\[[@CR94]\]Correction of mutations in exon 19 (c.2470insG) and exon 32 (c.3948insT) through homology-directed repair in iPSC\[[@CR42]\]Gene reframing therapy to a recurrent frameshift mutation, c.5819delC\[[@CR43]\]Correction of the mutation c.8068_8084delinsGA\[[@CR95]\]Cas9/sgRNA ribonucleoproteins to excise exon 80 in skin stem cells of recessive dystrophic EB mice\[[@CR96]\]Targeted deletion of mutation-bearing *COL7A1* exon 80 in RDEB patient keratinocytes\[[@CR39]\]Correction of a frequent inherited mutation in exon 80\[[@CR40]\]JEB/*LAMB3In situ* correction of *LAMB3* gene in keratinocytes\[[@CR97]\]EBS/*KRT14*Correction of the hotspot missense mutation c.1231G \> A in keratinocytes\[[@CR26]\]RNA-based therapiesRDEB/*COL7A1*Trans-splicing to correct mutations in the 3′ region\[[@CR98]\]SIN lentiviral vector at 3′ RNA trans-splicing molecule, capable of replacing exons 65--118\[[@CR99]\]2′-O-methyl ASO for skipping exons 73 and 80\[[@CR58]\]ASO for in-frame exon 105 skipping\[[@CR59]\]ASO for in-frame exon 13 and 105 skipping\[[@CR60]\]EBS/*KRT14*Therapeutic RNA trans-splicing molecule containing wild-type exons 1--7\[[@CR25]\]*ASO* antisense oligonucleotides, *EB* epidermolysis bullosa, *EBS* EB simplex, *iPSC* induced pluripotent stem cells, *JEB* junctional EB, *RDEB* recessive dystrophic EB, *SIN* self-inactivating

Molecular Pathology of Epidermolysis Bullosa (EB) {#Sec2}
=================================================

Pathogenic variants in 16 genes cause the four main subtypes of classical EB: EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB) and Kindler EB; over 30 EB subtypes are further defined based on clinical and molecular criteria \[[@CR2]\]. EBS and JEB are genetically heterogeneous, whereas DEB and Kindler EB are caused by mutations in single genes, *COL7A1* and *FERMT1*, respectively. In addition to the classical forms of EB, five additional genes have been associated with skin fragility disorders in differential diagnosis of EB. Thus, a total of 21 genes are known to harbor mutations in skin fragility disorders in the spectrum of EB.

The determinants of the EB phenotype include the identity of the affected gene/protein system and the specific nature of the disease-causing genetic variants. Specifically, residual amounts or functions of the affected protein versus its complete absence or loss-of-function determine whether the disease will be relatively mild, intermediate or severe. Examples of genotype--phenotype correlations in patients with JEB and DEB have shown that small amounts (even less than 10%) of proteins with partial function may result in a mild/intermediate phenotype \[[@CR4]--[@CR7]\]. Genetic and epigenetic disease modifiers may also play a modulating role but have only been experimentally demonstrated in a few cases \[[@CR8]--[@CR12]\], and such findings have to be extrapolated to larger numbers of patients to allow general conclusions. Socio-economic environment and access to medical care are also critical elements in determining the natural history of the disease and the development of complications in individual cases.

Although multiple different proteins are affected, it is widely accepted that all EB types have life-long skin fragility in common and this pathology (disruption of the barrier function of the skin and mucous membranes) leads to chronic tissue damage and associated inflammation. Loss of epidermal integrity is accompanied by bacterial colonization and activation of mechanisms of innate and adaptive immunity. The cytokines engaged in the tissue damage/repair processes depend on the extent of the mucocutaneous defects and on the level of blister formation (implying either cytolysis or basement membrane zone disruption), and include interleukin (IL)-1, IL-6 and transforming growth factor (TGF)-β \[[@CR13]--[@CR15]\]. With time, the ongoing regeneration processes affect the stem cells and the underlying connective tissue, leading to chronic, non-healing wounds. If these events affect a significant percentage of the body surface (such as more than 20--30% at any given time) over a long period, the "inflammation" becomes systemic, as shown by leukocytosis, increased C reactive protein and increased levels of immunoglobulins (IgG, IgM and IgA) \[[@CR16]\]. In recessive DEB (RDEB), involvement of the oral and esophageal mucosa impairs feeding, and---together with the high energetic requirements in the context of permanent wound healing---will lead to impaired growth and low body weight. The EB-associated symptoms---pain and pruritus---are mainly related to mucocutaneous blistering and wounding. A long-term complication of chronic tissue damage is carcinogenesis, which is reflected by high risk for squamous cell carcinomas (SCCs) at a young age in patients with RDEB \[[@CR17]\] and Kindler EB \[[@CR18], [@CR19]\]. Based on these considerations, the main rationale for therapy should be the correction of the skin adhesion defect as this is traditionally accepted as the main origin of pathogenic events in EB.

Precision Medicine for EB: From Genetic Defect to Therapeutic Approach {#Sec3}
======================================================================

In EB, knowledge of the precise underlying genetic defect is the prerequisite for any molecular therapy approach. The affected gene or protein and the type of pathogenic variants and their consequences dictate which gene or protein should be replaced or edited (e.g., gene or protein therapy). Patients with premature termination codon (PTC) mutations in any EB gene may benefit from read-through therapies \[[@CR20]--[@CR23]\]. Mutations in the type VII (*COL7A1*) and XVII (*COL17A1*) collagen genes, in which the majority of the exons are in frame, may be approached by skipping of the exons containing the mutations \[[@CR24]\]. In the autosomal-dominant forms of EBS and in dominant DEB, the vast majority of mutations lead to amino acid substitutions that disturb the formation and the stability of the keratin intermediate filaments or anchoring fibrils, respectively, through dominant-negative interference of the wild-type allele. For such mutations, potential strategies include knock-down/out of the mutated allele (e.g., by small interfering RNA, RNA trans-splicing or CRISPR/Cas9) \[[@CR25], [@CR26]\] or prevention of misfolding (e.g., with chaperones). More palliative (and less precise) approaches include the so-called symptom-relieving therapies, which are directed against inflammatory or other perturbed pathways (e.g., IL-1β, TGFβ). Generation of dedicated databases of EB-associated pathogenic variants comprising their biological characterization, such as consequences at splicing, protein and cellular levels as well as allele frequencies, would be of benefit for researchers and physicians dealing with EB and would assist in setting priorities for specific strategies and in stratification of patients for therapies.

Overview of Molecular Therapies in Development for EB {#Sec4}
=====================================================

Various molecular therapies are currently in preclinical or clinical development, and most of these focus on RDEB. An overview of the recent advances in those currently under development follows.

Gene-Replacement Therapies {#Sec5}
--------------------------

Many laboratories, in both academia and the pharmaceutical sector, have focused on gene-replacement approaches, particularly delivery of *COL7A1* to the skin of patients with RDEB (Table [1](#Tab1){ref-type="table"}). For details on methods, hurdles and risks, we refer to recent review articles \[[@CR27], [@CR28]\]. Some studies have tested the efficacy of topical application of an expression vector harboring full-length *COL7A1* complementary DNA (cDNA), which would then allow expression of the proα1(VII) polypeptides in the skin, followed by their incorporation into trimeric type VII collagen molecules and supramolecular assembly into functional anchoring fibrils.

In one such approach (Krystal Biotech, Inc.), the cDNA is packaged into a herpes simplex virus (HSV) delivery construct with epidermotropism. In this case, the HSV virus, which in its natural form is highly antigenic, has been modified to manifest with reduced immunogenicity, which would prevent development of immunological complications, such as formation of antibodies, which would eliminate the viral vector and preclude multiple applications (NCT03536143). Another topical application (Amryt Pharma, PLC) utilizes a recently developed non-viral carrier, a highly branched poly(β-ester) polymer, that allows delivery of the *COL7A1* cDNA into the skin. In both cases, the transgene does not integrate into the recipient's genome, and continuous---perhaps life-long---application is required to achieve sustained benefits from the treatment. Current early clinical trials are exploring the frequency of application required for maintenance of efficacy and are examining the levels of expression and turnover time of type VII collagen and its potential assembly into anchoring fibrils.

Another approach for delivery of *COL7A1* into patients with RDEB entails introduction of the transgene into the patient's own cells in cultures, with subsequent delivery of the corrected cells back into the skin. One such approach (Castle Creek Biosciences, Inc.) corrects autologous fibroblasts in culture with a vector that leads to integration of the transgene into the genome, followed by direct injection of the corrected cells to the edges of the wounds. This approach necessitates multiple injections, which can be painful, to the eroded areas of skin, and how long the corrected resident fibroblasts are present and remain active in situ is unclear. Another company (Abeona Therapeutics, Inc.) cultures autologous keratinocytes from the skin of patients with RDEB, followed by genetic correction ex vivo and development of epidermal sheaths, which can then be grafted to the denuded areas of the patient's skin \[[@CR29], [@CR30]\]. These studies have utilized a lentiviral vector that allows incorporation of the *COL7A1* cDNA into the genome of the recipient cells. Preliminary studies have revealed that the gene-corrected keratinocytes in the graft are capable of expressing type VII collagen, and there is evidence of assembly of anchoring fibrils. Of some concern is the durability of this approach since the early published data suggested that the expression of the collagen gene may fade over time, possibly attesting to the fact that the transgene is driven by a viral promoter or that the number of stem cells initially isolated and targeted were too low to sustain expression or possibly the graft \[[@CR31]\]. Furthermore, in some cases, the graft fails after a certain time, potentially necessitating regrafting of the area. In this context, a recent study demonstrated that correction of both keratinocytes and fibroblasts (cell types that in normal skin both synthesize type VII collagen) is required for optimal assembly of the anchoring fibrils \[[@CR32]\]. In this study, skin grafts were made by combining gene-corrected keratinocytes with type VII collagen-deficient fibroblasts, or, conversely, type VII collagen-deficient keratinocytes in combination with gene-corrected fibroblasts, or both cell types being gene corrected. All these three combinations of cells in skin-equivalent explant culture ex vivo expressed type VII collagen, but only the grafts in which both keratinocytes and fibroblasts were gene corrected showed assembly of functional anchoring fibrils. In keeping with these data, there is an ongoing effort to develop skin grafts (GENEGRAFT) that combine keratinocytes and fibroblasts in which both cell types have been corrected with a self-inactivating viral vector expressing type VII collagen \[[@CR33]\].

Epidermal grafts have been shown to be highly successful in correcting the underlying defect in patients with intermediate or localized JEB with defects in one of the laminin 332 genes, *LAMB3* \[[@CR33]--[@CR35]\]. The difference with these studies and those published on grafting in patients with RDEB is that the grafts for patients with JEB were made of a holoclone stem cell population, thus ensuring the longevity of the cells after transplantation. In fact, in one patient with JEB, the functionality of the skin grafts was retained several years after the transplantation \[[@CR36]\]. The difference in the outcome between the epidermal cells corrected for transplantation into patients with RDEB and JEB may also reside in the observation that, in normal skin, the laminin 332 polypeptide subunit genes, *LAMA3*, *LAMB3* and *LAMC2*, provide a selective advantage for retaining stem cells in vivo \[[@CR37], [@CR38]\].

Gene Editing {#Sec6}
------------

In addition to gene-replacement approaches, a number of studies have attempted gene repair, such as correction of the mutation by CRISPR/Cas9 editing technology \[[@CR39]--[@CR43]\] (Table [2](#Tab2){ref-type="table"}). For details on gene-editing strategies and their appropriate selection depending on mutation, gene and disease type, we refer to a recent overview article \[[@CR44]\]. Improvements in this technology have resulted in a high yield of gene correction in keratinocytes or fibroblasts derived from patients with RDEB, with subsequent development of skin grafts that have been transplanted into immunocompromised mice, demonstrating their capability of functional type VII collagen synthesis. One of the potential limitations of this approach is the requirement for a large number of cultured cells for graft production, and an innovative way to circumvent this limitation would be the development of iPSCs that, following the gene correction, can be differentiated into either keratinocytes or fibroblasts \[[@CR42], [@CR45]\].

Natural Gene Therapy {#Sec7}
--------------------

An intriguing possibility for cell-based therapy in EB is provided by revertant mosaicism, a phenomenon described as "natural gene therapy," in which a number of skin cells undergo spontaneous reversal of the mutation to wild-type genotype, resulting in areas of normal skin \[[@CR46], [@CR47]\]. The mechanisms of the mutation reversion are multiple, including mitotic recombinations, back mutations and second site mutations \[[@CR48]--[@CR50]\].

Revertant mosaicism in patients with RDEB has been primarily documented in keratinocytes, but evidence of revertant mosaic fibroblasts has also recently been reported \[[@CR51]\]. Attempts to establish long-term cultures of keratinocytes from areas of skin with revertant mosaicism have been mostly unsuccessful, primarily due to depletion of stem cells in the affected skin. However, punch grafting of revertant skin to isolated lesions in patients with laminin 332-deficient JEB has been reported \[[@CR52]\]. Transplantation of the biopsy specimens resulted in re-epithelialization of the wounds, but punch grafting allowed only a limited expansion of the revertant skin \[[@CR53]\]. However, expansion of the treated area can be achieved by generation of iPSCs from revertant keratinocytes, and these cells can then be differentiated into genetically corrected keratinocytes \[[@CR45]\]. These revertant iPSCs can be used to create three-dimensional skin equivalents ex vivo and reconstitute human skin in vivo, developing cell-based therapeutic approaches for EB.

Exon Skipping {#Sec8}
-------------

Exon skipping makes use of antisense oligonucleotides (ASOs) to modify the splicing of pre-messenger RNA (mRNA) and consequently eliminate the mutation responsible for a disease. Antisense-mediated exon skipping was initially developed for the treatment of Duchenne muscular dystrophy (DMD) and evolved into clinical trials to target *DMD* (dystrophin gene) exons with recurrent mutations, such as exons 45, 53 and 51. Eteplirsen (Exondys 51) is the first approved antisense therapy for DMD in the USA and provides a treatment option for the \~ 14% of patients with DMD who are amenable to exon 51 skipping \[[@CR54]\].

The rationale for using exon skipping in EB comes from studies of genotype--phenotype correlations showing that exon skipping can ameliorate the severity of JEB and DEB \[[@CR4], [@CR55]--[@CR57]\] and from the fact that most *COL17A1* and *COL7A1* exons are in frame. Several preclinical studies have demonstrated that skipping of exons 13, 70, 73, 80 or 105 in *COL7A1* results in slightly shortened, partially functional protein, which is deposited at the DEJZ \[[@CR58]--[@CR61]\] (Table [2](#Tab2){ref-type="table"}). A clinical trial testing topical administration of QR-313, a water-based gel (hydrogel) containing the ASO targeting exon 73 that will be applied directly onto DEB wounds for *COL7A1* correction is currently ongoing (Wings Therapeutics; NCT03605069).

Protein Therapy {#Sec9}
---------------

Preclinical studies have shown that recombinant type VII collagen, injected locally or intravenously, homes to the DEJZ and promotes wound healing \[[@CR62], [@CR63]\]. Recombinant type VII collagen has obtained fast drug designation from the US FDA, and a phase I/II clinical trial evaluating its safety and tolerability, as well as clinical proof of concept in adults with RDEB, is ongoing in the USA (Phoenix Tissue Repair, Inc.; NCT03752905). The advantages of systemically administered recombinant type VII collagen include the possibility that the protein, in addition to homing into skin, will reach extracutaneous tissues affected by RDEB, such as the gastrointestinal track and the cornea of the eye, with subsequent repair.

Beside this protein-replacement approach, a therapy with a high mobility group box 1 (HMGB1) fragment is under development (redasemtide trifluoroacetate phase II, Shinogi & Co., Ltd.). HMGB1 can mobilize the Lin(−)/PDGFRα(+) cells from bone marrow to damaged tissue and facilitate tissue repair \[[@CR64]\], probably by suppressing the inflammation of injured skin \[[@CR65]\]. In animal models, systemic administration of the HMGB1 fragment has shown benefits, preventing deterioration of cardiac performance in the delta-sarcoglycan-deficient hamster \[[@CR66]\] and ameliorating cutaneous and non-cutaneous manifestations in a dystrophic EB model mouse \[[@CR67]\].

Read-Through Therapies {#Sec10}
----------------------

The read-through approach involves the use of small-molecular-weight compounds that allow the translational machinery to suppress nonsense mutations by incorporating an amino acid in place of a stop codon and results in synthesis of full-length protein.

The original prototype of such read-through molecules, PTC124, was shown to read-through only pathogenic PTCs but not through naturally occurring endogenous stop codons of translation because the nucleic acid context and the intron--exon organization of the gene provide a very robust and strong stop signal. This read-through molecule has been tested on a number of genes, principally the dystrophin gene in DMD \[[@CR68]\], but some studies have failed to identify PTC124 as being able to efficiently read-through *COL7A1* PTCs as compared with the prototypic PTC read-through drug, the aminoglycoside gentamicin \[[@CR20], [@CR23], [@CR69]\]. Work has shown that gentamicin can effectively read-through *COL7A1* and *LAMB3* PTCs \[[@CR20], [@CR21]\], and clinical studies in RDEB have shown promising results \[[@CR22]\]. Long-term systemic treatment with this antibiotic has a number of potential issues, including the risk of renal toxicity \[[@CR70]\], and topical application might be a favorable delivery route in this context. Nevertheless, clinical studies testing the effect of intravenous injections of gentamicin are being conducted for RDEB (NCT03392909) and JEB (NCT03526159).

Another compound recently shown to induce read-through of *COL7A1* is amlexanox \[[@CR71]\], a drug with a number of different activities and targets currently in trial for a wide range of indications. This drug could potentially be used long term because of its very favorable toxicity profile and clinical history. However, the current manufacturer of amlexanox, Takeda Pharmaceutical, has removed it from the market, and an alternative supply will be needed to pursue clinical application. One interesting observation from the amlexanox study in EB was that it enhanced read-through only in cells with a low level of endogenous full-length protein, whereas cells with undetectable protein did not respond \[[@CR23]\]. These data suggest that certain cellular conditions required for read-through need to be identified and exploited for more efficient and effective approaches.

Small Molecules Repurposed to Relieve Symptoms {#Sec11}
----------------------------------------------

Fibrosis is a major pathological complication of RDEB, and work with patient cells in culture, animal models and patients have all identified TGFβ signaling as a major driver of fibrosis and disease severity \[[@CR9], [@CR72]--[@CR75]\]. TGFβ is a primary mediator of fibrosis driving extracellular matrix (ECM) deposition in numerous pathological situations, and considerable effort has focused on understanding and inhibiting TGFβ in a number of contexts \[[@CR76]\]. However, as TGFβ receptors participate in a signaling pathways that control many aspects of mammalian development and tissue homeostasis, global inhibition has proven problematic \[[@CR77]\]. Indirect targeting of molecules that activate or inhibit the pathway in specific contexts will likely have improved efficacy compared with global inhibition. The first example of such an approach in RDEB is the use of losartan, a drug approved for the treatment of high blood pressure. Work in animal models identified a significant reduction of fibrosis in the paws of hypomorphic mice with losartan treatment, and this drug is now in a clinical trial (EudraCT number: 2015-003670-32) \[[@CR78]\]. The mechanism here is thought to be a reduction in blood pressure, which reduces the bioavailability or release of TGFβ ligand from the fibrotic ECM. Other preclinical efforts have used viral delivery of decorin, an inhibitor of TGFβ, to show reduced paw fibrosis in mouse models \[[@CR79]\], whereas in vitro work with patient cells has suggested that inhibition of thrombospondin-1, a potent activator of TGFβ, may have clinical efficacy \[[@CR72]\]. In addition to these academic-led initiatives, a number of anti-TGFβ antibodies are in development in the commercial space that have potential to reach clinical trial in the coming years.

Therapies for EB-Associated Squamous Cell Carcinoma {#Sec12}
===================================================

Historically, only a few reports have documented any durable therapeutic response of SCCs in patients with RDEB, and the observations that reported short-term responses were not followed-up in the literature \[[@CR80]\]. However, additional case studies and reviews of prior literature are beginning to emerge, and the main focus has been on cetuximab, the epidermal growth factor receptor inhibitor approved for head and neck SCC (HNSCC) \[[@CR81]\]. A number of patients with RDEB have been treated, and progression-free survival has been reported to range between 3 and 9 months, but wound-healing deficits are often noted, and eventually the patients may succumb to their disease \[[@CR82]--[@CR86]\]. With the recent approval of the immune checkpoint inhibitors nivolumab, pembrolizumab and cemiplimab, the treatment landscape of HNSCC and cutaneous SCC is changing, and long-term progression-free survival in a small proportion of patients with spontaneous SCC is becoming evident \[[@CR87], [@CR88]\]. For two patients with RDEB SCC treated with nivolumab, the results were negative, with no evidence of durable response \[[@CR82], [@CR86]\]. However, two patients are too few to rule out potential benefits, considering that only \~ 20% of patients with HNSCC show a response to this therapeutic approach. One phase I clinical trial testing the toxicity of isotretinoin in RDEB SCC has been reported \[[@CR89]\]. Although the drug was well-tolerated by 20 patients, no further studies were conducted. Preclinical work identified the potential of the multikinase inhibitor rigosertib, an experimental therapeutic in phase III trials for treatment of myelodysplastic syndrome and RDEB SCC \[[@CR90]\]. In cell culture and animal studies, rigosertib induced apoptosis in RDEB SCC without adversely affecting non-SCC RDEB epidermal keratinocytes. As a result, two trials, one in the USA (NCT04177498) and one in the UK and Austria (NCT03786237), have been initiated.

Conclusions and Future Perspectives {#Sec13}
===================================

Tremendous progress has been made in understanding the molecular genetics and underlying pathomechanisms of different forms of EB, and the increase in knowledge about these disorders has formed the basis for treatment development. Several laboratories in academia, a number of companies and biotechnology and the "big pharma" have devoted a considerable amount of effort and resources to develop treatments and cures for EB. Such approaches include gene replacement and repair, protein replacement and cell-based therapies, and some are allele specific, requiring knowledge of mutant genes and specific mutations. A number of these strategies are in early clinical trials, and at least three are entering phase III for clinical testing in 2020. Considering the multiplicity of approaches, there is cautious optimism that some drugs may emerge in the near future as potential candidates for treatment of EB. It has also been suggested that, because of the complementary nature of these approaches, application of different drugs in combination may result in optimal treatment outcomes for an individual with EB \[[@CR100]\].

Despite significant progress and relatively numerous ongoing clinical trials, the number of patients with EB who currently have access to molecular therapies is limited (Table [1](#Tab1){ref-type="table"}). Current development is also primarily focused on DEB and JEB, whereas EBS, the most common EB type, has been largely neglected even though affected individuals are severely impaired in everyday life and professional activities. Furthermore, there are several questions regarding the cost of development and delivery of such pharmaceuticals and global access to these drugs once they are available in the market.

Regenerative medicine and replacement of the deficient genes and proteins are the only way to "cure" EB. Nevertheless, "adjuvant" therapies with less expensive repurposed drugs may assist in reducing disease severity and improving the quality of life of the affected individuals. In fact, such therapies may be required to complement strategies aimed at alleviating the fragility of the skin and mucous membranes as the primary pathologic process. Also, proving the efficacy of such measures seems challenging, and designing clinical trials with better endpoints and sufficient numbers of participants requires long-term expertise and international collaboration. Nevertheless, patients with EB and their families are looking forward to effective treatment, hopefully before too long.
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